glp 1 vs glp 1ra GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Vs Tirzepatide: Powerful Guide
Description
This ensures that patients receive the most benefits while maintaining safety
Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Spending on shareholder enrichment appears to take priority over research and development (R&D), with Novo Nordisk spending 41% more on dividends and buybacks than on R&D over the past five years
The potential reward is finding an effective oral GLP-1 solution before it becomes mainstream
The series, authored by RWJF Senior Policy Adviser Katherine Hempstead, analyzes changes in the individual market
